CRSP · Company research

CRISPR Therapeutics AG

4 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

Trial resultsCRSPCRISPR2026

CRISPR expects to report results from its Phase 1 study of CTX320 / CTX321 for Elevated lipoprotein(a) / ASCVD during 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.

More details

Entry

Lp(a) program (CTX320/CTX321) update expected in 2026 · Clinical trial results (readout / topline data)

Drug

CTX320 / CTX321

For

Elevated lipoprotein(a) / ASCVD

Stage

Phase 1 · an early safety study in a small group of people

When

2026 · the company gave a window, not a day

Source note

Q2 2026 release (Aug 3, 2026) reiterates JPM 2026 guidance. CTX320 showed up to 73% Lp(a) reduction in dose escalation; next-gen CTX321 (~2x potency guide RNA) is advancing.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
CRSP headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsCRSPCRISPRH2 2026

CRISPR expects to report results from its Phase 1 study of Zugocabtagene geleucel (zugo-cel, formerly CTX112) for Autoimmune (SLE, SSc, myositis, ITP, wAIHA) and B-cell malignancies in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.

More details

Entry

Zugo-cel (CTX112) updates across autoimmune disease and immuno-oncology · Clinical trial results (readout / topline data)

Drug

Zugocabtagene geleucel (zugo-cel, formerly CTX112)

For

Autoimmune (SLE, SSc, myositis, ITP, wAIHA) and B-cell malignancies

Stage

Phase 1 · an early safety study in a small group of people

When

H2 2026 · the company gave a window, not a day

Source note

Jan 12, 2026 milestones PR: 'Updates across autoimmune disease and immuno-oncology for zugocabtagene geleucel... are expected in the second half of 2026.'

Checked

Checked by a person when it was added

Verify it

Source: crisprtx.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
CRSP headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsCRSPCRISPRH2 2026

CRISPR expects to report results from its Phase 2 study of CTX611 (siRNA) for Thromboembolism prevention in total knee arthroplasty in the second half of 2026 (no exact date yet). Phase 2 is the stage that tests whether the drug actually works.

More details

Entry

CTX611 Phase 2 topline in total knee arthroplasty (VTE prevention) · Clinical trial results (readout / topline data)

Drug

CTX611 (siRNA)

For

Thromboembolism prevention in total knee arthroplasty

Stage

Phase 2 · the stage that tests whether the drug actually works

When

H2 2026 · the company gave a window, not a day

Source note

Jan 12, 2026 milestones PR: 'Top-line Phase 2 clinical data from CTX611 in patients undergoing total knee arthroplasty (TKA) are expected in the second half of 2026.'

Checked

Checked by a person when it was added

Verify it

Source: crisprtx.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
CRSP headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsCRSPCRISPRH2 2026

CRISPR expects to report results from its Phase 1b study of CTX310 for Severe hypertriglyceridemia / refractory hypercholesterolemia in the second half of 2026 (no exact date yet). This is the first look at whether the drug did what the company hoped.

More details

Entry

CTX310 ANGPTL3 Ph1b clinical update (sHTG/refractory hypercholesterolemia) · Clinical trial results (readout / topline data)

Drug

CTX310

For

Severe hypertriglyceridemia / refractory hypercholesterolemia

Stage

Phase 1b

When

H2 2026 · the company gave a window, not a day

Source note

Q2 2026 release (Aug 3, 2026). Separate from the already-listed ESC Aug 28 durability late-breaker; Phase 1b prioritizes sHTG and refractory hypercholesterolemia.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
CRSP headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

ConferenceCRSPCRISPRAug 28, 2026

CRISPR presented data on CTX310 for ANGPTL3-driven dyslipidemias (sHTG, refractory hypercholesterolemia) at a medical meeting on Aug 28, 2026. The linked source has the details.

More details

Entry

CTX310 durability late-breaker at ESC Congress 2026 · Data presented at a medical meeting

Drug

CTX310

For

ANGPTL3-driven dyslipidemias (sHTG, refractory hypercholesterolemia)

Stage

Phase 1 · an early safety study in a small group of people

When

Aug 28, 2026

Source note

Q2 2026 PR (Aug 3, 2026): late-breaking abstract on durability of CTX310 effects accepted at the European Society of Cardiology Congress in Munich on August 28, 2026. Prior data: peak TG reduction 82%, LDL 86%.

Checked

Checked by a person when it was added

Verify it

Source: globenewswire.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
CRSP headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ApprovalCRSPCRISPRJul 2, 2026

The FDA approved CRISPR’s CASGEVY (exagamglogene autotemcel) for Sickle cell disease and transfusion-dependent beta thalassemia on Jul 2, 2026. The company can now sell it in that market.

More details

Entry

FDA approves CASGEVY for sickle cell and beta thalassemia patients ages 2+ · Regulatory approval

Drug

CASGEVY (exagamglogene autotemcel)

For

Sickle cell disease and transfusion-dependent beta thalassemia

Stage

Regulatory (sBLA label expansion)

When

Jul 2, 2026

Source note

FDA approved expanded use of the Vertex/CRISPR-partnered CASGEVY (exagamglogene autotemcel) for people ages 2 and older with sickle cell disease with recurrent VOCs or transfusion-dependent beta thalassemia, the first genetic therapy indicated for children as young as 2 in both diseases. CRSP shares rose on the news.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
Drugs@FDA ↗ — search the drug name for approval letters
CRSP headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ApprovalCRSPCRISPRDec 8, 2023

The FDA approved CRISPR’s Casgevy (exa-cel) for Sickle cell disease on Dec 8, 2023. The company can now sell it in that market.

More details

Entry

FDA approval of Casgevy: first CRISPR therapy · Regulatory approval

Drug

Casgevy (exa-cel)

For

Sickle cell disease

When

Dec 8, 2023

Source note

Vertex/CRISPR exa-cel approved for sickle cell disease.

Checked

Checked by a person when it was added

Verify it

SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
Drugs@FDA ↗ — search the drug name for approval letters
CRSP headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to CRSP.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.